Paris: Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said that the clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data to the Drugs Controller General of India (DCGI) next month.
Talking to the media, Dr Ella said, "We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world's first clinically proven nasal COVID-19 vaccine". Krishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.
In January this year, India's drug controller gave Bharat Biotech permission to conduct standalone phase III trials on its COVID-19 nasal vaccine. On the booster dose of COVID-19, Krishna said that those who had taken the second dose must take the booster dose.
"Booster dose of vaccine gives immunity. I always say the booster dose is a miracle dose for every vaccination. Even in children first, two doses don't give much immunity, but the third dose gives an amazing response to the child. The same thing for adults also. The third dose is very important for adults. COVID-19 can't be eradicated 100 per cent. It will be there and we have to live with it and handle it and more intelligently how to control it," he said.